Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.

about

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.

Item

http://www.wikidata.org/entity/Q42373342

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cytoreductive nephrectomy for ...... ist despite improved survival.

@en

Cytoreductive nephrectomy for ...... ist despite improved survival.

@nl

type

Item

label

Cytoreductive nephrectomy for ...... ist despite improved survival.

@en

Cytoreductive nephrectomy for ...... ist despite improved survival.

@nl

prefLabel

Cytoreductive nephrectomy for ...... ist despite improved survival.

@en

Cytoreductive nephrectomy for ...... ist despite improved survival.

@nl

P1476

Cytoreductive nephrectomy for ...... ist despite improved survival.

@en

P2093

Albert Bang

http://www.w3.org/2001/XMLSchema#string

David P Smith

http://www.w3.org/2001/XMLSchema#string

Kieran Beattie

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoreductive surgery in the era of targeted molecular therapy

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

P304

2188-2193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1137

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Howard Gurney

Manish I Patel

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28834281

http://www.w3.org/2001/XMLSchema#string

P932

5633591

http://www.w3.org/2001/XMLSchema#string